Breaking News

Akari Initiates Manufacturing Activities to Support AKTX-101 Development

WuXi XDC to provide necessary IND-enabling work for AKTX-101 to support the initiation of clinical trials.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Akari

Akari Therapeutics, Plc, an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, announced the initiation of GMP manufacturing activities to support the development of AKTX-101, the company’s lead ADC program. Akari has selected WuXi XDC, a contract development and manufacturing organization (CDMO), as its partner to provide necessary IND-enabling work to support the initiation of clinical trials.  The initiation of manufacturing activity marks a s...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters